EN DE

Accendra Health Inc (ACH) Fair Value & Analysis

Healthcare · US · Market cap $238M · ISIN US6907321029

AH Accendra Health Inc logo Accendra Health Inc ACH · US
Price$1.21
Fair Value$0.9944
Upside-17.8%
Quality40/100
Watch Accendra Health Inc for free, get notified when fair value or trend changes. Watch for free

Risks

!Trades 22% ABOVE our fair value of $0.9944
!Weak Growth (revenue 5y −20.1 %/yr)
!Loss-making · -39.8% net margin
!Negative equity (buybacks among others) · negative free cash flow
Weak Growth (revenue 5y −20.1 %/yr)
Loss-making · -39.8% net margin
Negative equity (buybacks among others) · negative free cash flow
Trails peers (4/11)
Narrow moat 11/100
Evidence: Low Range $0.5917 – $0.9944 Share as image

Fair value as of: Aug 13, 2026

From 3 valuation models · updated 15 days ago

Fair value updated Aug 13, 2026, revised from $2.21 to $0.9944 (−55.0%) since Jul 14, 2026. Share price −62.8% over the past month.

Below-average quality, and trading another 22% above our fair value.

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Track Accendra Health Inc and get told automatically when its fair value or trend turns, plus fair value for all 35,000+ stocks. 14 days of Pro free, no card. Track it free

What matters now

  • The price sits above even our optimistic bull case ($0.9944). The favourable scenario is already priced in.
  • Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$48.31 $0.9500 Fair Value $0.9944 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range $0.9500 – $48.31 · fair‑value band $0.5917 – $0.9944 · the $1.21 price screens above the $0.9944 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Accendra Health Inc (ACH) currently trades at $1.21, while our model-based Fair Value estimate is $0.9944, implying the stock looks roughly 17.8% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Accendra Health Inc generated revenue of $2.7B at a net margin of -39.8%. Revenue declined 6.8% year over year. Net debt stands at $2.0B. Fundamentals as of Aug 13, 2026

Our scenario range runs from $0.5917 (bear case) to $0.9944 (bull case); at $1.21, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -9% fair-value upside, at -18%, ACH screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
EV/EBITDA $11.76 $18.26 $24.75 54
EV/EBIT $2.02 $5.27 $8.51 53
EV/Revenue $2.21 $5.19 43
All 3 models by family
Multiples
EV/EBIT $2.02 $5.27 $8.51 53
EV/EBITDA $11.76 $18.26 $24.75 54
EV/Revenue $2.21 $5.19 43

Notify me when ACH reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 0.09 TTM
EPS (TTM) $-1.37
Net margin -39.8% FY2025
Return on equity -198% TTM
Return on assets (EBIT) 3.4% avg 5y
Operating margin -1.0% TTM
More key figures
Growth
Revenue (TTM) $2.7B TTM
Revenue growth (YoY) -6.8% 3y avg -34.8%
Balance sheet & cash flow
Free cash flow −$303M FY2025
Net debt $2.0B FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 40/100

Of which business quality 38 · Market factors (momentum, volatility) 5

Profitability 44
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 1
Earnings quality: real cash, not paper profit
Fin. Strength 11
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 7
Calm price path (market factor)
Momentum 6
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 79
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous …

Full company description

Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Accendra Health Inc reported revenue of $2.8B in FY2025 versus $9.8B in FY2021, a compound −27.1%/yr. Reported net income was −$1.1B in FY2025.

Growth Quality 0/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
$2.8B
Latest YoY
−74.2%
Avg. revenue growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−34.8%
Avg. revenue growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−20.1%
Avg. revenue growth/yr (40Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.2%
Value creation/yr We only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Revenue −27.1%/yr
FY21 $9.8B
FY22 $10.0B
FY23 $10.3B
FY24 $10.7B
FY25 $2.8B
Net income
FY21 $222M
FY22 $22.4M
FY23 −$41.3M
FY24 −$363M
FY25 −$1.1B

ACH screens 18% overvalued. Compare with McKesson Corporation →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Accendra Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/ACH

Peer Group

Medical Distribution · 81 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 40 · Bottom 25%
Fair Value upside −18% · Below median
Return on assets 2% · Below median
Net margin (TTM) -40% · Bottom 25%
Operating margin (TTM) -1% · Bottom 25%
Revenue growth -7% · Bottom 25%

Valuation Multiples vs Medical Distribution median · lower = cheaper

P/S (TTM) 0.09× · Cheaper than 75% of peers
EV/EBITDA 5.4× · Cheaper than median
PEG 0.70× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE9 · sector 23
FUTURE0 · sector 17
PAST0 · sector 22
HEALTH100 · sector 97
DIVIDEND0 · sector 50

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $896.65 $819.31 -9%
Cencora, Inc COR $327.79 $211.07 -36%
Cardinal Health, Inc CAH $238.40 $141.77 -41%
Henry Schein, Inc HSIC $88.46 $71.70 -19%
Shanghai Pharmaceuticals Holding 601607 ¥16.37 ¥33.96 +107%
Sinopharm Group 1099 HK$16.75 HK$58.67 +250%
Galenica AG GALE CHF 80.85 CHF 61.79 -24%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥21.03 ¥28.65 +36%
Jointown Pharmaceutical Group 600998 ¥5.04 ¥9.84 +95%
Asker Healthcare Group ASKER kr 74.40 kr 28.26 -62%

Compare Accendra Health Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Fama-French 3-Factor Model Calculator Run the Fama-French 3-factor model in seconds: expected return from the market, size and value factors - free, with formula, betas and an example. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Accendra Health Inc (ACH) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of $0.9944 versus a price of $1.21, about −18% (overvalued).
What is the fair value of ACH?
Our model-based fair value for Accendra Health Inc is $0.9944 (as of Aug 13, 2026), built from audited fundamentals. The current price: $1.21.
What is the quality score of ACH?
Accendra Health Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Accendra Health Inc (ACH)?
Accendra Health Inc reported trailing-twelve-month revenue of about $2.7B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of ACH?
The net profit margin of Accendra Health Inc is about -39.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

Free · no account needed

Watch Accendra Health Inc in the live analysis

One click puts Accendra Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.